Although the association with the changes of body weight remains unclear, it has been reported that the SGLT2 inhibitor canagliflozin improves liver dysfunction in patients with T2DM, assessed by serum ALT and γ-GTP levels [37]. This evidence concerns the gene GPT and Decreased liver function.